The Physique & Metabolic Stack: TRT + GLP-1s + Tesamorelin

Body composition is the physical foundation that most men are trying to optimize, whether they articulate it that way or not. When a man says he wants to “lose the gut,” “get in shape,” or “look better,” what he is actually describing is a shift in body composition: less fat (particularly visceral fat), more lean muscle, and improved metabolic markers that support long-term health. The challenge is that after 35, the hormonal environment is actively working against this goal.

Testosterone declines, making muscle harder to build and easier to lose. Insulin sensitivity deteriorates, making your body more efficient at storing calories as fat. Growth hormone drops, reducing your capacity for fat oxidation and tissue repair. And appetite regulation becomes dysregulated as metabolic signaling pathways lose their precision. This is why the man who could stay lean eating whatever he wanted at 25 now gains weight just by looking at a pizza.

This stack addresses all three of these problems simultaneously. TRT restores the anabolic foundation. GLP-1 receptor agonists (semaglutide or tirzepatide) fix appetite regulation and insulin sensitivity. Tesamorelin specifically targets the visceral fat that wraps around your organs and drives metabolic disease. Together, they create the most effective body recomposition framework available in hormone optimization today.

Pillar 1: TRT as the Anabolic Foundation

In the context of body composition, testosterone is your metabolism's control signal. It determines the balance between anabolic (tissue-building) and catabolic (tissue-breaking) processes. When testosterone is optimized, your body preferentially partitions nutrients toward muscle protein synthesis rather than fat storage. When testosterone is low, the reverse happens: muscle is catabolized for energy while fat accumulates, particularly in the visceral compartment.

The research on testosterone and body composition is some of the most robust in the TRT literature. Multiple randomized controlled trials have demonstrated that testosterone replacement therapy in hypogonadal men consistently produces fat loss (primarily visceral), lean mass gains (even without structured exercise), improved insulin sensitivity, and increased basal metabolic rate. The landmark TRAVERSE trial and its sub-studies confirmed significant body composition improvements in men receiving TRT versus placebo, with the effect being most pronounced in men with the highest baseline body fat.

Dosing for Body Recomposition

For body composition purposes, the TRT dose is typically standard replacement: 100-160mg per week of testosterone cypionate or enanthate, titrated to achieve total testosterone in the 700-1000 ng/dL range with free testosterone in the upper quartile. The rationale for the slightly higher target compared to the longevity stack is that the anabolic effects of testosterone are dose-dependent within the physiological range, and body recomposition benefits from more anabolic signaling.

• Dose: 100-160mg per week testosterone cypionate or enanthate
• Injection frequency: 2-3 times per week, subcutaneous or intramuscular
• Target total testosterone: 700-1000 ng/dL (mid-to-upper physiological range)
• Free testosterone: Upper quartile of reference range
• Key monitoring: Hematocrit (keep below 54%), estradiol via sensitive assay, lipid panel

Pillar 2: GLP-1 Receptor Agonists for Appetite and Metabolic Control

GLP-1 receptor agonists, primarily semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), have fundamentally changed the landscape of weight management. These are not traditional diet drugs. They are synthetic versions of a naturally occurring gut hormone, glucagon-like peptide-1, that your body uses to regulate appetite, insulin secretion, and glucose metabolism.

The clinical trial data for these compounds is extraordinary by any standard. The STEP and SURMOUNT trial programs demonstrated average weight loss of 15-22% of body weight over 68-72 weeks, with tirzepatide (which targets both GLP-1 and GIP receptors) showing the highest efficacy. These results are unprecedented for any pharmacological weight loss intervention in history. But the raw weight loss numbers only tell part of the story, and for men running TRT, the more important effects are the metabolic improvements.

Why GLP-1 Agonists Matter Beyond Appetite Suppression

The popular narrative around GLP-1 drugs reduces them to “appetite suppressants,” but this dramatically undersells their mechanism. These compounds:

• Improve insulin sensitivity: By restoring proper insulin signaling, GLP-1 agonists help your body use glucose efficiently rather than storing it as fat. This is critical for men with metabolic syndrome or prediabetes
• Reduce hepatic glucose output: The liver is a major driver of elevated blood sugar. GLP-1 agonists reduce inappropriate glucose dumping from the liver
• Slow gastric emptying: This creates more stable blood sugar responses to meals, reducing insulin spikes and the subsequent fat storage signal
• Reduce food noise: Many users report that the constant mental preoccupation with food, what to eat next, cravings, and the urge to snack, simply disappears. This is a central nervous system effect that changes the relationship with food
• Cardiovascular protection: The SELECT trial showed a 20% reduction in major adverse cardiovascular events with semaglutide in overweight adults, independent of its weight loss effects
• Reduce systemic inflammation: GLP-1 agonists have demonstrated significant reductions in inflammatory markers like hsCRP, which is relevant for both cardiovascular health and overall healthspan

Semaglutide vs. Tirzepatide: Which One?

Both compounds are effective, but they differ in meaningful ways:

• Semaglutide is a pure GLP-1 receptor agonist. It has the longest track record, the most safety data, and demonstrated cardiovascular benefit (SELECT trial). Typical maintenance dosing is 1.0-2.4mg weekly by subcutaneous injection. GI side effects (nausea, constipation) are common during dose titration but usually resolve
• Tirzepatide is a dual GLP-1/GIP receptor agonist. It produces approximately 5-7% more weight loss than semaglutide at equivalent doses and may preserve more lean mass due to its GIP activity. Typical maintenance dosing is 5-15mg weekly by subcutaneous injection. GI side effects are similar but some users tolerate it better

Neither compound is clearly “better” for all men. Semaglutide has more long-term safety data and cardiovascular evidence. Tirzepatide may produce better body composition outcomes. Many practitioners start with semaglutide due to the longer safety track record and switch to tirzepatide if additional efficacy is needed.

Pillar 3: Tesamorelin for Targeted Visceral Fat Reduction

Tesamorelin is a synthetic growth hormone releasing hormone (GHRH) analog consisting of 44 amino acids. It is the only compound in this stack that is FDA-approved for a specific fat-reduction indication: the treatment of excess abdominal fat (lipodystrophy) in HIV-infected adults. While its FDA approval is limited to this population, the mechanism of action, stimulating your pituitary to produce more growth hormone, is universal.

What makes Tesamorelin particularly interesting in a body composition stack is its specificity for visceral adipose tissue (VAT). Visceral fat is the metabolically dangerous fat that wraps around your internal organs (liver, intestines, pancreas) and is the primary driver of metabolic syndrome, insulin resistance, and cardiovascular disease. Unlike subcutaneous fat (the fat you can pinch), visceral fat is highly responsive to growth hormone signaling, and Tesamorelin exploits this by increasing local GH-driven lipolysis specifically in the visceral compartment.

Clinical Evidence

The evidence for Tesamorelin's efficacy in reducing visceral fat is among the strongest of any peptide used in optimization protocols, precisely because it went through the FDA approval process:

• Phase III trials showed an average 15-18% reduction in visceral fat over 26 weeks of daily use, as measured by CT scan
• Improvements in triglyceride levels and other lipid markers
• Reductions in trunk fat without significant changes in subcutaneous fat or extremity fat (demonstrating the visceral specificity)
• Improvements in IGF-1 levels through physiological GH stimulation
• Maintained benefits over 52 weeks of continued treatment in extension studies

The key insight is that Tesamorelin does not produce dramatic weight loss on a scale. A man might lose 3-5 pounds of visceral fat over six months, which barely registers on the scale but produces measurable reductions in waist circumference, significant improvements in metabolic blood markers, and reduces the most dangerous form of body fat.

Protocol Framework

• Dose: 2mg daily via subcutaneous injection (this is the FDA-approved dose)
• Timing: Typically bedtime on an empty stomach (at least 2 hours after eating) to align with natural GH pulsatility and avoid insulin interference
• Duration: Minimum 6 months for meaningful results; many men run it for 9-12 months
• Injection site: Abdominal subcutaneous tissue, rotating injection sites
• Monitoring: IGF-1 levels at baseline and 4-8 weeks, fasting glucose, HbA1c

How the Three Work Together

This stack is not three unrelated compounds thrown together. Each addresses a specific failure point in the body composition equation, and together they create a system where each compound amplifies the others:

• TRT + GLP-1 agonist: The GLP-1 agonist creates the caloric deficit and insulin sensitivity improvement needed for fat loss. TRT ensures that the weight lost is primarily fat, not muscle. Without TRT, the aggressive caloric reduction from GLP-1 drugs would cannibalize lean tissue. Without the GLP-1, many men on TRT still struggle with appetite regulation and insulin resistance
• TRT + Tesamorelin: Testosterone improves overall body composition and metabolic rate. Tesamorelin specifically targets the visceral fat that testosterone alone may not fully address. The combined anabolic environment (elevated testosterone + elevated GH from Tesamorelin) creates optimal conditions for both fat loss and lean mass preservation
• GLP-1 + Tesamorelin: The GLP-1 agonist addresses appetite and insulin resistance (the behavioral and metabolic drivers of fat gain). Tesamorelin addresses the stubborn visceral depot that is often the last fat to respond to conventional weight loss. The insulin sensitivity improvements from the GLP-1 also create a better hormonal environment for the GH-driven lipolysis that Tesamorelin relies on

Training and Nutrition: The Non-Negotiables

This stack is powerful, but it does not replace the fundamentals. In fact, the fundamentals become more important, not less, when running this combination because they determine whether the weight you lose is predominantly fat or a mixture of fat and muscle.

Resistance Training

Structured resistance training 3-4 times per week is non-negotiable when using GLP-1 agonists. The mechanical stimulus of lifting weights is the primary signal that tells your body to preserve muscle tissue during caloric deficit. Without this signal, even with TRT, you will lose more lean mass than necessary. The training does not need to be extreme. Compound movements (squat, deadlift, bench press, rows, overhead press) performed with progressive overload at 3-4 sessions per week is sufficient.

Protein Intake

Protein intake becomes critical when appetite is suppressed by GLP-1 agonists. Many men on semaglutide or tirzepatide struggle to eat enough protein because their appetite is dramatically reduced. This creates a muscle-loss risk that must be actively managed. Target a minimum of 0.8-1g of protein per pound of target body weight daily. If your goal weight is 200 pounds, eat at least 160-200g of protein per day. Protein shakes, protein bars, and prioritizing protein at every meal help manage this when appetite is low.

Hydration and Electrolytes

GLP-1 agonists slow gastric emptying, which can reduce fluid intake. Tesamorelin can affect fluid balance through GH-mediated mechanisms. And TRT may increase hematocrit, requiring adequate hydration to maintain blood viscosity. Drinking at least half your body weight in ounces of water daily, with added electrolytes (sodium, potassium, magnesium), is a baseline recommendation when running this stack.

Bloodwork and Monitoring Protocol

This stack requires more comprehensive monitoring than most because you are affecting three distinct systems simultaneously:

• Baseline (before starting): Complete metabolic panel, lipid panel, HbA1c, fasting insulin, testosterone (total and free), SHBG, estradiol (sensitive), hematocrit/CBC, IGF-1, liver enzymes, thyroid panel (TSH, free T3, free T4), hsCRP
• 4-6 weeks: Follow-up testosterone, estradiol, hematocrit (TRT monitoring), IGF-1 (Tesamorelin efficacy), fasting glucose (GLP-1 monitoring)
• 12 weeks: Comprehensive panel including all baseline markers to assess progress and identify any needed adjustments
• Ongoing: Every 3 months for the duration of the protocol

Special attention should be paid to fasting glucose and HbA1c (should be improving on GLP-1; if not, investigate), hematocrit (TRT-related; keep below 54%), IGF-1 (should increase on Tesamorelin but not exceed the upper reference range), lipid panel (should improve; if LDL rises significantly, investigate), and liver enzymes (baseline monitoring for any multi-compound protocol).

Side Effects and Risk Management

Each compound in this stack carries its own side effect profile, and they should be understood individually:

• TRT side effects: Covered extensively in our TRT Guide. Primary concerns are hematocrit elevation, estrogen management, and fertility suppression (see our Fertility Stack if planning children)
• GLP-1 agonist side effects: Gastrointestinal effects are the most common: nausea (40-44% in trials), diarrhea, constipation, and vomiting. These typically reduce after the titration period. Rare but serious: pancreatitis (very rare, <0.5%), gallbladder events (slightly elevated risk with rapid weight loss), and potential thyroid concerns (C-cell tumors in rodent studies, not confirmed in humans but contraindicated with personal or family history of medullary thyroid carcinoma or MEN2)
• Tesamorelin side effects: Injection site reactions (redness, swelling), joint pain or stiffness, fluid retention, and potential impact on glucose metabolism. Contraindicated in individuals with active malignancy, as elevated GH can promote tumor growth

The Bottom Line

The physique and metabolic stack is the most comprehensive pharmacological approach to body composition optimization currently available for men. TRT restores the anabolic hormonal foundation that makes lean mass preservation possible during caloric deficit. GLP-1 receptor agonists solve the behavioral and metabolic problems (appetite dysregulation, insulin resistance) that drive fat accumulation. Tesamorelin attacks the most dangerous fat depot directly through GH-mediated visceral lipolysis.

But compounds without fundamentals are a waste. Resistance training, adequate protein, proper sleep, and consistent hydration are the non-negotiable behaviors that determine whether this stack produces a lean, muscular, metabolically healthy result or a slightly thinner version of the same metabolic dysfunction. The pharmacology creates the environment for transformation. The lifestyle habits determine whether you actually transform.

If you are considering this stack, start with our TRT Comprehensive Guide to understand the hormonal foundation. Review the Bloodwork Blueprint so you know which markers to test. And find a provider experienced in metabolic optimization who can prescribe and monitor these compounds appropriately (see Find a Provider).